Enovis CORP(ENOV)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,147 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in ENOV
Events flagged as statistical outliers against ENOV's own multi-year baseline — not fixed dollar thresholds.
- Insider cluster2026-09-04
2 insiders bought $399,591 of ENOV in 30 days — 3.6σ above this company's 2-year norm
View source filing →
ENOV Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Enovis CORP (ENOV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ENOV at 39.5/100 on a 32-signal composite quality model, placing it at rank #2,147 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (9.3) and profitability (10.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 46.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Enovis CORP reports quarterly revenue of $582.8M, net income of $-1.2M, free cash flow of $31.1M. Top institutional holders of ENOV by reported 13-F value include BlackRock, AMERICAN CENTURY COMPANIES, Context Capital Management, based on the most recent SEC filings. ENOV trades on the NYSE exchange and files with the SEC under CIK 1420800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENOV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Enovis CORP directly from SEC EDGAR. Enovis CORP's 13F Pro composite quality score has ranged between 28 and 46 since 2022, currently 39.5 — a stable long-term trajectory across 63 quarterly and live scoring snapshots.
Revenue
Q2 2026
$582.8M
Net Income
Q2 2026
$-1.2M
Free Cash Flow
Q2 2026
$31.1M
ROIC
Q2 2026
2.5%
D/E Ratio
Q2 2026
0.89
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+6.7% YoYNet Income
-43.5% YoYOperating Income
-44.9% YoYEPS (Diluted)
-39.0% YoYTotal Assets
-18.7% YoYTotal Debt
-1.3% YoYOp. Cash Flow
+91.4% YoYFree Cash Flow
+129.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.25B +6.7% | $2.11B +23.5% | $1.71B +9.2% | $1.56B +9.6% | $1.43B +27.3% | $1.12B |
| Net Income | $-1.18B -43.5% | $-825.5M -2381.9% | $-33.3M -150.2% | $-13.3M -118.5% | $71.7M +68.1% | $42.6M |
| Operating Income | $-1.12B -44.9% | $-775.7M -1080.5% | $-65.7M +7.7% | $-71.2M -13.3% | $-62.8M +5.1% | $-66.2M |
| EPS (Diluted) | $-20.75 -39.0% | $-14.93 -2347.5% | $-0.61 -144.0% | $-0.25 -117.9% | $1.40 +50.5% | $0.93 |
| Total Assets | $3.83B -18.7% | $4.72B +4.6% | $4.51B +5.5% | $4.27B -49.8% | $8.52B +15.8% | $7.35B |
| Total Debt | $1.33B -1.3% | $1.35B +189.5% | $466.2M -2.6% | $478.6M -77.1% | $2.09B -7.3% | $2.26B |
| Operating Cash Flow | $217.3M +91.4% | $113.5M -15.9% | $135.0M +341.6% | $-55.9M -115.7% | $356.1M +17.9% | $301.9M |
| Free Cash Flow | $19.9M +129.6% | $-67.2M -626.5% | $12.8M +107.9% | $-161.3M -164.0% | $251.9M +34.6% | $187.2M |
Get alerted when ENOV's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Enovis CORP including:
Top Institutional Holders of ENOV
BlackRock, Inc.
$213.1M10,295,666 shAMERICAN CENTURY COMPANIES INC
$126.4M6,106,561 shContext Capital Management, LLC
$115.4M119,688,000 shLINDEN ADVISORS LP
$102.7M106,748,000 shVANGUARD PORTFOLIO MANAGEMENT LLC
$81.3M3,926,268 shRubric Capital Management LP
$80.7M3,900,000 shVANGUARD CAPITAL MANAGEMENT LLC
$51.4M2,484,318 shSTATE STREET CORP
$51.0M2,462,788 shDAVENPORT & Co LLC
$48.5M2,341,521 shHood River Capital Management LLC
$47.6M2,299,326 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $213.1M | 10,295,666 |
| AMERICAN CENTURY COMPANIES INC | $126.4M | 6,106,561 |
| Context Capital Management, LLC | $115.4M | 119,688,000 |
| LINDEN ADVISORS LP | $102.7M | 106,748,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $81.3M | 3,926,268 |
| Rubric Capital Management LP | $80.7M | 3,900,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $51.4M | 2,484,318 |
| STATE STREET CORP | $51.0M | 2,462,788 |
| DAVENPORT & Co LLC | $48.5M | 2,341,521 |
| Hood River Capital Management LLC | $47.6M | 2,299,326 |
Companies Similar to ENOV
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
QuidelOrtho Corp
TANDEM DIABETES CARE INC
CONMED Corp
DENTSPLY SIRONA Inc.
AdaptHealth Corp.
Teladoc Health, Inc.
PERRIGO Co plc
Orthofix Medical Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ENOV on your watchlist
Track score changes the day Enovis CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ENOV a good stock to buy?
13F Pro's AI-powered analysis of Enovis CORP (ENOV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENOV are available on the ENOV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ENOV is classified as a small company.
Which hedge funds own ENOV?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENOV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Enovis CORP's investment landscape.